Where to consult authoritative recommendations and distinguish them from historical PDFs.
Italy: AIOM and the National Guideline System
AIOM’s catalogue and the Italian National Institute of Health’s National Guideline System provide access to Italian documents, their producers, status and versions. Guidelines found online have not all undergone the same methodological assessment. Before using a PDF, check its title page, update date and scope: cutaneous melanoma, melanocytic lesions, uveal melanoma and non-melanoma skin cancers are different subjects.
The SNLG melanoma document updated in 2023 and guidance on histopathological and molecular diagnosis of melanocytic lesions are identifiable catalogue references; check for subsequent updates. A PDF does not become a “2026 guideline” simply because it was consulted in 2026. For medicines in Italy, also check AIFA: a scientific recommendation does not automatically establish reimbursement.
Sources: AIOM — Linee guida: catalogo ufficiale; ISS — Sistema Nazionale Linee Guida; AIFA — Agenzia Italiana del Farmaco.
International references and audiences
ESMO published its cutaneous melanoma guideline for diagnosis, treatment and follow-up in Annals of Oncology in 2025. It is a professional document and should be read alongside any later updates. NICE NG14 provides accessible recommendations and rationales within a UK organisational context. The National Cancer Institute’s PDQ offers evidence summaries, references and professional or patient versions.
AAD provides dermatological guidance, while EADO offers dermato-oncology resources and activities. These sources may differ in details, particularly surveillance and rare situations. Differences should not be resolved by independently choosing the most intensive protocol; discuss them with the team familiar with the case.
Patients can note an unclear recommendation and ask how it applies to their stage, age, health and preferences. Professionals should assess evidence quality, recommendation strength, study population and declared conflicts. Patient guides support understanding rather than serving as simplified prescriptions.
Sources: ESMO — Cutaneous melanoma guideline, 2025; NICE NG14 — melanoma, recommendations; NCI — Melanoma Treatment (PDQ); EADO — European Association of Dermato-Oncology.
How the historical collection is handled
The original collection included AAD, Australian and New Zealand documents, ASCO sentinel node guidance, ESMO, HAS, AGENAS, European consensus, German, SIGN and 2010 UK documents, plus dermoscopy material. Several destinations have moved or are unavailable. Locally retained PDFs are presented as an archive with an explicit warning that they are not a current protocol.
It is unsafe to present 2008–2012 follow-up schedules or treatment algorithms as current. Check historical documents’ dates and producers, and return to the official sources above for present-day decisions. Foot, nail and dermoscopy topics remain relevant to education, but should be connected to updated diagnostic information rather than used for photographic self-diagnosis.
Sources: AIOM — Linee guida: catalogo ufficiale; ESMO — Cutaneous melanoma guideline, 2025.
Historical PDF archive, not current protocols
- AAD guidelines of care for primary cutaneous melanoma — document from the 2010–2011 collection
- Australian melanoma guidelines — document from the 2010–2011 collection
- Dermoscopy guidelines — document from the 2010–2011 collection
- Linee Guida Italiane sul Melanoma — document from the 2010–2011 collection
- Melanoma Guidelines European Consensus-based Interdisciplinary Guideline — document from the 2010–2011 collection
- U.K. guidelines for the management of cutaneous melanoma 2010 British Journal of Dermatology — document from the 2010–2011 collection
Editorial review and source consultation: 17 October 2026. Educational information, not individual healthcare or benefits advice. Source checking does not certify a new specialist clinical validation.